Patents by Inventor Constance Martin

Constance Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING
    Publication number: 20260176619
    Abstract: The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, hematopoietic stem cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
    Type: Application
    Filed: February 24, 2025
    Publication date: June 25, 2026
    Inventors: Matthew G. Stanton, Phillip Samayoa, Nathaniel Silver, Douglas A. Rose, Constance Martin, Nolan Gallagher, Lalita Oonthonpan, Jimit G. Raghav, Christian J. Slubowski, Anshul Gupta, Sandy Zhang, Anthony Joseph Perniciaro, Sachit Shah
  • STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING
    Publication number: 20260041643
    Abstract: The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
    Type: Application
    Filed: February 20, 2025
    Publication date: February 12, 2026
    Inventors: Matthew G. Stanton, Phillip Samayoa, Nathaniel Silver, Douglas A. Rose, Constance Martin, Nolan Gallagher, Lalita Oonthonpan, Jimit G. Raghav, Christian J. Slubowski, Anshul Gupta, Sandy Zhang, Anthony Joseph Perniciaro
  • STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING
    Publication number: 20250281647
    Abstract: The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
    Type: Application
    Filed: February 26, 2025
    Publication date: September 11, 2025
    Inventors: Matthew G. Stanton, Phillip Samayoa, Nathaniel Silver, Douglas A. Rose, Constance Martin, Yao Xin, Tiffany Alysia Tate
  • TGF-BETA INHIBITORS AND USE THEREOF
    Publication number: 20250282857
    Abstract: The present disclosure provides TGF? inhibitor therapy for treating immunosuppressive conditions, such as cancer. Methods of predicting and monitoring therapeutic response are disclosed. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: March 25, 2022
    Publication date: September 11, 2025
    Inventors: Si Tuen LEE-HOEFLICH, Christopher BRUECKNER, Constance MARTIN, Ryan FAUCETTE
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20250257125
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: February 4, 2025
    Publication date: August 14, 2025
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20250215072
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: September 17, 2024
    Publication date: July 3, 2025
    Inventors: Abhishek Datta, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. Dagbay, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • Methods of screening for high-affinity, isoform-selective TGF?1 inhibitors
    Patent number: 12252531
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: March 18, 2025
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • Isoform-selective TGFB1 inhibitors and use thereof
    Patent number: 12122823
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: October 22, 2024
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • TGF-BETA INHIBITORS AND THERAPEUTIC USE THEREOF
    Publication number: 20240294623
    Abstract: The present disclosure provides TGF? inhibitor therapy for treating immunosuppressive conditions, cancer, and fibrosis, either as a monotherapy or combination/adjunct therapy. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and fibrosis and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 5, 2024
    Inventors: Lu GAN, Thomas SCHURPF, George CORICOR, Justin William JACKSON, Si Tuen LEE-HOEFLICH, Christopher BRUECKNER, Constance MARTIN, Ryan FAUCETTE
  • ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20240016928
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: August 1, 2023
    Publication date: January 18, 2024
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
  • TGF-BETA INHIBITORS AND USE THEREOF
    Publication number: 20230050148
    Abstract: The present disclosure provides TGF? inhibitor therapy for treating immunosuppressive conditions, such as cancer. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 16, 2023
    Inventors: Ashish Kalra, Thomas Schurpf, Adam Fogel, Christopher Brueckner, Alan Buckler, Constance Martin, Si Tuen Lee-Hoeflich
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20220064275
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: August 19, 2021
    Publication date: March 3, 2022
    Inventors: Abhishek DATTA, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. DAGBAY, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • Isoform-selective TGF?1 inhibitors and use thereof
    Patent number: 11130803
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 28, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210122814
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 29, 2021
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • LRRC33 INHIBITORS AND USE THEREOF
    Publication number: 20200181251
    Abstract: Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.
    Type: Application
    Filed: May 9, 2018
    Publication date: June 11, 2020
    Inventors: Alan Buckler, Gregory J. Carven, Stefan Wawersik, Thomas Schurpf, Constance Martin, Abhishek Datta, Mark Allen Farmer
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20200079840
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: March 12, 2020
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson
  • ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20190209682
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: March 22, 2019
    Publication date: July 11, 2019
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
  • ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20180207267
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: January 5, 2018
    Publication date: July 26, 2018
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler